The burgeoning field of obesity management has witnessed remarkable advancements with the emergence of dual GLP-3 receptor agonists, notably Retatrutide and Trizepatide. These novel therapies represent a significant https://kaitlyndqwu355193.theobloggers.com/45252212/glp-3-receptor-agonists-retatrutide-trizepatide